product within NIAID would submit an Employee Invention Report to the NIH

Summary

Document 1-12 in Case 2:21-cv-00702-CLM, Filed 05/19/21; stamped as filed in the U.S. District Court, N.D. of Alabama. The document, headed Gov/Big Pharma Conflict, states that the mRNA-1273 vaccine was developed by NIAID scientists and collaborators at Moderna, Inc. It asserts that inventors within NIAID stand to receive a personal payment of up to $150k annually from sales and that HHS awarded $483 million to accelerate development. A later section lists members of the FDA Vaccines and Related Biological Products Advisory Committee with notes on reported payments from companies. It states that the items come from a quick preliminary check and that plaintiffs intend to conduct a more thorough investigation before trial.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

1

Gov/Big Pharma Conflict

The vaccine is called mRNA-1273 and was developed by NIAID scientists and their
collaborators at the biotechnology company Moderna, Inc., based in Cambridge,
Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI)
supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an
urgent public health priority,” said NIAID Director Anthony S. Fauci, M.D. “This
Phase 1 study, launched in record speed, is an important first step toward achieving
that goal.”1
To receive a share of the profit from the sale of mRNA-1273, the inventors of this
product within NIAID would submit an Employee Invention Report to the NIH
Office of Technology transfer. 2 Each inventor stands to receive a personal payment
of up to $150k annually from the sales of mRNA-1273.3 In addition, NIAID stands
to earn millions of dollars in revenue from the sale of mRNA-1273.4

Moderna will pay license fee to NIAID to use its patents related to mRNA-1273 and
a portion of those fees are then paid directly to the inventors within NIAID who
developed those patents.5

NIH has produced reports which confirm that these individuals are listed as
inventors.6
•
Barney Graham, Deputy Director, NIAID Vaccine Research Center
•
Kizzmekia Shanta Corbett, Scientific Lead, NIAID’s Coronavirus
Vaccine Program
•
Michael Gordon Joyce, NIAID
•
Hadi Yassine, NIAID
•
Masaru Kanekiyo, NIAID
•
Olubukola Abiona, NIAID
HHS awarded $483 million to accelerate development of mRNA-1273.7 The US
Government has reached a 1.525 billion deal to purchase 100 million doses of
mRNA-1273.8
In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics
(ADEPT) program awarded grant funding to Moderna Therapeutics for the
development of a new type of vaccine based on messenger RNA.  The initial DARPA
grant was W911NF-13-1-0417.  The company used that technology to develop its
COVID-19 vaccine, currently undergoing Phase I clinical trials in conjunction with
NIH.9
FILED
 2021 May-20  AM 11:34
U.S. DISTRICT COURT
N.D. OF ALABAMA
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 1 of 12

2

FDA Vaccines and Related Biological Products Advisory Committee Roster
Content current as of 4/9/2110

Any consideration of financial conflict of interest at the Vaccines and Related
Biological Products Advisory Committee must be set against the historical backdrop
of the profound financial conflicts of interest seen in the during the H1N1 pandemic
ten years ago.  At that time, five of the sixteen experts were found to have ties to
the pharmaceutical industry.  There were “calls from the British Medical Journal,
to release the names of committee members and their conflicts of interest, in the
interest of transparency and to monitor any possible commercial influence.”  That
earlier “pandemic has proved profit-making for the industry, with one estimate (by
JP Morgan) putting 2009 vaccine profits alone at $7-10 billion.”11

There appear to be significant conflicts of interest today especially among
committee leaders.  The items reported in this memo are the results of a quick
preliminary check on conflicts and are not a complete representation.  Plaintiffs
intend to conduct a more thorough investigation before trial.

Chair
Hana El Sahly, M.D.
Expertise: Vaccines, Infectious Diseases
Term: 06/21/2019-01/31/2022
Professor
Department of Molecular Virology and Microbiology
Department of Medicine
Section of Infectious Diseases
Baylor College of Medicine
Houston, TX 77030
hanae@bcm.edu

• Top FDA vaccine adviser recuses herself over tie to Moderna.12
• Associate Professor Baylor.  She currently serves as the Principal
Investigator of the Vaccine and Treatment Evaluation Unit at Baylor College
of Medicine.13
• Federal database shows since 2013 $693,001.78 in general payments and
$5,315,014.60 in research payments made to “Chi St. Lukes Health Baylor
Med Ctr” – 6720 Bertner Ave, Houston, TX from various companies.14
• Dr. El Sahly was appointed as one of three lead investigators for Moderna’s
30,000-person trial in July.  Reuters reported that Dr. El Sahly had to recuse
herself from an important committee meeting on Oct. 22, 2020.15, 16   There
are multiple citations of this. e.g. 17, 18, 19 & 20   Ironically, there is no
compensation of Dr. El Sahly reported on the openpaymentsdata.cms.gov
website.  This raises serious questions as to the completeness of the conflict
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 2 of 12

3

data reported on that site.  The University of Florida Conflicts of Interest
Program and the Project on Government Oversight reported conflicts of
interest of Drs. El Sahly, Monto, and Chaterjee.21, 22

Paula Annunziato, M.D
Expertise: Industry Representative
Term: 02/01/2020-01/31/2024
Vice President and Therapeutic Area Head
Vaccines Clinical Research
Merck
North Wales, PA 19454

• Past (or current?) involvement in supervising Moderna’s Covid-19 vaccine
clinical trial.23
• Not listed in the openpaymentsdata.cms.gov website.

Acting Chair
Arnold Monto, M.D.
Thomas Francis Jr. Collegiate Professor of Public Health
Professor of Epidemiology
Department of Epidemiology University of Michigan
School of Public Health
Ann Arbor, MI 48109
• Acting chairman of the committee, Dr. Arnold Monto received $54,114
from 2013 through 2019 from vaccine contenders Sanofi,
GlaxoSmithKline, Pfizer, and Shionogi, according to the database. He also
received $10,657 from Novartis, which has a deal to manufacture a
coronavirus vaccine.24
• Dr. Monto received a total of $194,254 from pharmaceutical companies.25
The largest contributor was Seqirus, a company developing COVID vaccine in
Australia.26  The University of Florida Conflicts of Interest Program and the
Project on Government Oversight reported conflicts of interest of Drs. El
Sahly, Monto, and Chaterjee.27, 28

Archana Chatterjee, M.D., Ph.D.
Expertise: Pediatrics, Infectious Diseases
Term: 06/21/2019-01/31/2023
Dean Chicago Medical School
Vice President for Medical Affairs
Rosalind Franklin University of Medicine and Science
North Chicago, IL 60064
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 3 of 12

4

• A federal database shows that, in 2019, advisory committee member Dr.
Archana Chatterjee, for instance, received $23,904 from Pfizer (including Pfizer
International LLC), $11,738 from Merck, and $11,480 from Sanofi, each of which
is in the race for a coronavirus vaccine. Since 2013, she has received more than
$200,000 in consulting fees, travel and lodging, and other payments from those
companies and others working on coronavirus vaccines, according to the
database.29
• She is a professor of epidemiology at the University of Michigan, which has
announced that it is partnering with pharmaceutical company, AstraZeneca
on a clinical trial of a potential Covid-19 vaccine.30
• General payments to Dr Chaterjee total $245,810.  Associated research funding
totals $142,344.  Largest funders include: Pfizer Inc., Merck Sharp & Dohme
Corporation, Seqirus USA Inc., and AstraZeneca Pharmaceuticals.31  The
University of Florida Conflicts of Interest Program and the Project on
Government Oversight reported conflicts of interest of Drs. El Sahly, Monto, and
Chaterjee.32, 33

CAPT Amanda Cohn, M.D.
Expertise: Pediatrics, Vaccines
Term: 02/01/2020-01/31/2024
Chief Medical Officer
National Center for Immunizations and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30333
Telephone: (404) 639-6039
E-mail: acohn@cdc.gov
Hayley Gans, M.D.
Expertise: Pediatrics, Infectious Diseases
Term: 06/21/2019-01/31/2023
Professor of Pediatrics
Department of Pediatrics
Stanford University Medical Center
Stanford, CA 94305
Holly Janes, Ph.D.
Expertise: Biostatistics
Term: 02/01/2020-01/31/2023
Associate Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Division of Public Health Sciences
Seattle, WA 98109
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 4 of 12

5

Phone: 206.667.6353
Email: hjanes@fredhutch.org
Fax: 206.667.4378

Michael Kurilla, M.D., Ph.D.
Expertise: Infectious Diseases, Pathology
Term: 08/06/2018-01/31/2022
Director, Division of Clinical Innovation
National Center for Advancing Translation Sciences
National Institutes of Health
Bethesda, MD 20852
Michael.kurilla@nih.gov
Myron Levine, M.D., D.T.P.H., F.A.A.P
Expertise: Infectious Diseases
Term: 05/09/2018-01/31/2022
Simon & Bessie Grollman Distinguished Professor
Associate Dean for Global Health
Vaccinology and Infectious Diseases
Center for Vaccine Development
University of Maryland School of Medicine
Baltimore, MD 21201
• Dr. Myron Levine is associate dean for global health, vaccinology, and
infectious diseases at the University of Maryland School of Medicine. The
school is participating in a clinical trial of a COVID-19 vaccine being
developed by Moderna and the National Institute of Allergy and Infectious
Diseases.34
• Since 2013, for research in which Levine played a principal role,
GlaxoSmithKline has paid the University of Maryland Baltimore
Foundation Inc. and another institution more than $2.3 million.35
• Dr. Levine received general payments of $41,635 and associated research
funding of $2,314,178.  Dr. Levin’s 2019 funding was about six times the
mean of similar physicians.36  His largest source of funding was Sanofi
Pasteur who is developing a COVID vaccine as above.37

• UM School of Medicine's Myron M. Levine, MD, DTPH, to Receive
Prestigious Lifetime Award for Five Decades of Pioneering Vaccine
Research38
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 5 of 12

6

• Was on a WHO sponsored advisory group that considered feasibility of doing
Covid-19 challenge studies in young, healthy volunteers.  No conflict of
interest declared.  Also on the panel was Sheng-Li Shi from WIV.39
H. Cody Meissner, M.D. (aka Herman Meissner)
Expertise: Infectious Diseases
Term: 08/06/2018-01/31/2022
Professor of Pediatrics
Tufts University School of Medicine
Director, Pediatric Infectious Disease
Tufts Medical Center
Boston, MA 02111
• Tufts Children’s Hospital - Division of Pediatric Infectious Disease.  Head of
all clinical trials for all of Tufts Children’s Hospital.40
• Since 2013, Tufts University has been paid general payments of
$13,241,677.43 by companies including Pfizer, Boston Scientific, Gyrus Acmi,
Inc., Janssen Scientific, Biogen, Inc., Bayer Healthcare, Sanofi-Aventis,
Genentech, Otsuka Pharmaceutical, Amgen, Inc.41
• Since 2013, Tufts University has been paid research payments of
$34,183,399.06 by companies including Pfizer, Inc., Merck Sharp & Doh,
Shire North America, Abiomed, Gilead Sciences, Inc.)42
Paul Offit, M.D.
Expertise: Infectious Diseases
Term: 02/01/2018-01/31/2022
Professor of Pediatrics
Division of Infectious Diseases
Abramson Research Building
The Children’s Hospital of Philadelphia
Philadelphia, PA 19104
• Director of the Vaccine Education Center and an attending physician in the
Division of Infectious Diseases at Children's Hospital of Philadelphia.43
• Since 2013, The Childrens Hospital of Philadelphia has received general
payments of $4,559,116.78 and research payments of $32,013,340.94 from
companies including Spark Therapeutics, United Therapeutics, Novartis
Pharmaceiticals, Amgen, Inc., Pfizer, Inc.44
• Vaccine Safety: Myths and Misinformation.  No Conflict of Interest
Declared.45
• The science of vaccine safety: Summary of meeting at Wellcome Trust,
Conflict of interest statement: Declaration of Competing Interest The authors
declare that they have no known competing financial interests or personal
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 6 of 12

7

relationships that could have appeared to influence the work reported in this
paper.46
Steven Pergam, M.D.
Expertise: Infectious Diseases
Term: 02/01/2020-01/31/2024
Medical Director
Infection Prevention
Seattle Cancer Care Alliance
Seattle, WA 98109
Phone: 206.667.7126
Email: spergam@fredhutch.org
• Associate Professor, Vaccine and Infectious Disease Division, Fred Hutch
• Associate Professor, Clinical Research Division, Fred Hutch47
• Since 2013, Dr. Pergam has received $4167.00 in general payments from
Merck and Gilead and $140,311.19 research funding from Merck, Sharp and
Dohme. 48
• Potential conflicts of interest. A. L. G. reports personal fees from Abbott
Molecular outside the submitted work. S. A. P. reports grant support from
Global Life Technologies, Inc, participates in research trials with Chimerix,
Inc, and has participated in research with Merck & Co. He is currently
participating in a clinical trial sponsored by the National Institute of Allergy
and Infectious Diseases (NIAID; U01-AI132004); vaccines for that trial are
provided by Sanofi-Aventis.
Andrea Shane, M.D., M.P.H., M.Sc.
Expertise: Pediatric & Infectious Diseases
Term: 02/01/2018-01/31/2022
Professor of Pediatrics
Director
Division of Pediatric Infectious Diseases
Emory University School of Medicine
Atlanta, GA 30322
404-727-9880 (direct)
404-727-5642 (main)
Email: ashane@emory.edu
• Medical Director Children’s Healthcare of Atlanta; Curriculum vitae49
• Since 2013, Egleston Childrens Hospital at Emory has received $114,148.01
in general payments and $814,977.27 in research payments from companies
including Jazz Pharmaceuticals, Genmark Diagnostics, WL Gore &
Associates, etc.50
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 7 of 12

8

• Since 2013, Emery University Hospital has received $44,133,351.66 in
general payments and $170,711,591.68 in research payments.  At the top of
the research companies are ER Squibb & Sons and Pfizer, Inc.51
• Since 2013, Wesley Woods Center of Emory University has received
$41,205.70 in general payments and $3,429,327.48 in research payments.
Topping the research companies are E.R. Squibb & Sons and Janssen
Research. 52
Paul Spearman, M.D.
Expertise: Pediatric & Infectious Diseases
Term: 05/09/2018-01/31/2022
Director, Division of Infectious Diseases
Albert B. Sabin Chair in Pediatric Infectious Diseases
Cincinnati Children’s Hospital
Medical Center
Professor, Department of Pediatrics
University of Cincinnati School of Medicine
Cincinnati, OH 45229
513-636-4509
Paul.spearman@cchmc.org
• Between 2013-2015, Dr. Spearman received $39,459.84 in research funding
from Glaxosmithkline, LLC and Astrazenica.  No data available for years
2016-201953
• Since 2013, University of Cincinnati Medical Center has received
$2,236,276.81 in general payments and $4,281,617.38 in research payments.
Topping the list of companies on both accounts is Pfizer, Inc.54
• Had to be recused from some meetings because his hospital, Cincinnati
Children’s Hospital is also a COVID vaccine clinical trial site.55  Dr.
Spearman received $39,46060 in associated research funding primarily from
Glaxosmithkline, LLC. and AstraZeneca Pharmaceuticals LP.56
• No conflict of interest declared in Warp Speed for COVID-19 Vaccines: Why
are Children Stuck in Neutral?57

Conclusions: Children are at substantial risk of COVID-19. Delays in starting
Phase II vaccine clinical trials in children will delay our recovery from
COVID-19 and unnecessarily prolong its impact upon children’s health and
emotional well-being, their education, and equitable access to opportunities
for development and social success, as well as the country’s economy.
Understanding the safety, immunogenicity, and efficacy of COVID-19
vaccines in children is critical to protect children and adults. For children, a
vaccine has the added benefit of returning them safely to school and
extracurricular activities, and allowing them to engage with their world face-
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 8 of 12

9

to-face once again. Ensuring acceleration of vaccine clinical trials to warp
speed for children will be critical in making this our future reality.

Geeta K. Swamy, M.D.
Expertise: Infectious Diseases
Term: 08/06/2018-01/31/2022
Senior Associate Dean
Vice Chair for Research & Faculty Development
Associate Professor, ObGyn
Department of Obstetrics & Gynecology
Division of Maternal-Fetal Medicine
Duke University
Durham, NC 27710
• Since 2013, Dr. Swamy has received general payments of $63,040.09
(Glaxosmithkline, LLC, Sanofi, Pfizer, et al) and research payments of
$206,038.64 from Glaxosmithkline, LLC.58
• Since 2013, Duke University Hospital has received $7,599,234.72 in general
payments and $40,585,472.53 in research payments from various companies.
Pfizer, Inc. contributed general payments of $866,119.65 and research
payments of $2,677,484.45.59
• Dr. Swamy had to recuse herself from committee meetings because Duke
University, where she is associate vice president for research, is a clinical
trial site for the Pfizer-BioNTech and AstraZeneca vaccines.60  Dr. Swamy
received payments from pharmaceutical companies totaling $63,040.  Her
associated research funding totaled $206,039, about three times that of
similar physician. Dr. Swamy’s largest sources of funding are
Glaxosmithkline, LLC., Sanofi Pasteur Inc., Pfizer Inc. and Novartis
Vaccine.61
• Vaccination of pregnant women with respiratory syncytial virus vaccine and
protection of their infants.  Study funded by Novavax and the Bill and
Melinda Gates Foundation.62
Gregg Sylvester, M.D., M.P.H. +
Expertise: Alternate Industry Representative
Term: 02/01/2020-01/31/2024
Vice President
Medical Affairs
Seqirus Inc.
Summit, NJ 07901
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 9 of 12

10

• Chief Medical Officer, Seqirus - Dr Gregg Sylvester has led Seqirus Medical
Affairs since 2016, overseeing the global team that scientifically
differentiates our vaccines by generating Real World Evidence and
presenting Seqirus research to national vaccine recommending organizations.
• According to the Federal database, Seqirus USA, Inc. has made general
payments in the sum of $569,854.35 and research payments in the sum of
$44,159,881.83.  Topping the list of receivers of general payments are Arnold
Simon Monto and Archana Chatterjee.63
DIRECTOR
Prabhakara Atreya, Ph.D.
Division of Scientific Advisors & Consultants
Center for Biologics Evaluation & Research
Food and Drug Administration
Silver Spring, MD 20993
CBERVRBPAC@fda.hhs.gov

DR. MARION GRUBER
Director, FDA Vaccine Research Office

DESIGNATED FEDERAL OFFICER
Kathleen Hayes, M.P.H.
Division of Scientific Advisors & Consultants
Center for Biologics Evaluation & Research
Food and Drug Administration
Silver Spring, MD 20993
CBERVRBPAC@fda.hhs.gov

1 https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins
2 https://www.ott.nih.gov/resources
3 https://www.ott.nih.gov/royalty/information-nih-inventors
4 https://www.ott.nih.gov/resources
5 https://www.ott.nih.gov/royalty/information-nih-inventors
6 https://www.icandecide.org/wp-content/uploads/2020/08/NIH-FOIA-53821-Complete-Response-RS.pdf
7 https://investors.modernatx.com/node/8671/pdf
8 https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-supply-agreement-
us-government-initial-100
9 https://crsreports.congress.gov/product/pdf/IN/IN11446
10 https://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-
committee/roster-vaccines-and-related-biological-products-advisory-committee
11 https://www.ghwatch.org/who-watch/h1n1.html
12 https://www.foxnews.com/us/hana-sahly-vaccine-adviser-resign-covid
13 https://www.bcm.edu/people-search/hana-el-sahly-21052
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 10 of 12

11

14 https://openpaymentsdata.cms.gov/hospital/450193
15 https://www.bizjournals.com/boston/news/2020/09/25/fda-official-involved-in-moderna-trial-steps-aside.html
16 https://www.reuters.com/article/healthcoronavirus-vaccines-fda/exclusive-top-adviser-steps-aside-from-fda-
covid-19-vaccine-reviews-over-potential-conflict-idUSL2N2GK284
17 https://www.statnews.com/2020/10/20/dry-technical-but-important-why-an-fda-advisory-panels-meeting-on-
covid-19-vaccines-matters/
18 https://www.nbcdfw.com/news/coronavirus/texan-involved-in-covid-19-vaccine-trials-advises-against-half-
doses/2521936/
19 https://www.pbs.org/newshour/health/watch-live-fda-advisory-committee-assesses-covid-19-vaccine-
development
20 https://www.bizjournals.com/boston/news/2020/09/25/fda-official-involved-in-moderna-trial-steps-aside.html
21 https://coi.ufl.edu/2020/10/26/some-fda-advisors-tapped-to-review-coronavirus-vaccines-received-payments-
from-vaccine-companies/
22 https://www.pogo.org/investigation/2020/10/some-fda-advisors-tapped-to-review-coronavirus-vaccines-
received-payments-from-vaccine-companies/
23 https://finance.yahoo.com/news/fda-vaccine-committee-head-steps-
055718018.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQA
AALNseSAkcAU_oXgLmONgHMz3p4FUoRtEgZv6xLlCKnvY8bO_SPG8CWFhdbvZULO0xruuDmy7LlRVSQuQ_uWNGkX
o58YlBrjD2co7KOVu2CRMOwippqce1pb6QhT5efYM5OMtuWyPQ9K3EzyR5yg-u1v_7VSbFCdGLHIFDP1kiJhj
24 https://openpaymentsdata.cms.gov/physician/1311454
25 Id.
26 https://www.seqirus.us/news/covid19-update
27 https://coi.ufl.edu/2020/10/26/some-fda-advisors-tapped-to-review-coronavirus-vaccines-received-payments-
from-vaccine-companies/
28 https://www.pogo.org/investigation/2020/10/some-fda-advisors-tapped-to-review-coronavirus-vaccines-
received-payments-from-vaccine-companies/
29 https://coi.ufl.edu/2020/10/26/some-fda-advisors-tapped-to-review-coronavirus-vaccines-received-payments-
from-vaccine-companies/
30 https://www.uofmhealth.org/news/archive/202009/u-m-conduct-clinical-trial-test-astrazeneca-covid-19-
vaccine
31 https://openpaymentsdata.cms.gov/physician/803928
32 https://coi.ufl.edu/2020/10/26/some-fda-advisors-tapped-to-review-coronavirus-vaccines-received-payments-
from-vaccine-companies/
33 https://www.pogo.org/investigation/2020/10/some-fda-advisors-tapped-to-review-coronavirus-vaccines-
received-payments-from-vaccine-companies/
34 https://www.medschool.umaryland.edu/profiles/Levine-Myron/
35 https://openpaymentsdata.cms.gov/physician/1098730
36 Id.
37 https://www.sanofi.com/en/about-us/our-stories/sanofi-s-response-in-the-fight-against-covid-19
38 https://www.medschool.umaryland.edu/CVD/News-and-Events/2019/UM-School-of-Medicines-Myron-M-
Levine-MD-DTPH-to-Receive-Prestigious-Lifetime-Award-for-Five-Decades-of-Pioneering-Vaccine-Research.html
39 https://pubmed.ncbi.nlm.nih.gov/32857836/
40 https://www.tuftschildrenshospital.org/Patient-Care-Services/Departments-and-Services/Infectious-
Disease/Overview
41 https://openpaymentsdata.cms.gov/hospital/220116
42 https://openpaymentsdata.cms.gov/hospital/220116
43 https://www.chop.edu/doctors/offit-paul-a
44 https://openpaymentsdata.cms.gov/hospital/393303
45 https://pubmed.ncbi.nlm.nih.gov/32857836/
46 https://www.sciencedirect.com/science/article/pii/S0264410X20300396?via%3Dihub
47 https://www.fredhutch.org/en/faculty-lab-directory/pergam-steven.html
48 https://openpaymentsdata.cms.gov/physician/44476
49 https://fda.report/media/117726/VRBPAC-AndreaLShane-CV.pdf
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 11 of 12

12

50 https://openpaymentsdata.cms.gov/hospital/113300
51 https://openpaymentsdata.cms.gov/hospital/110010
52 https://openpaymentsdata.cms.gov/hospital/110203
53 https://openpaymentsdata.cms.gov/physician/1036685
54 https://openpaymentsdata.cms.gov/hospital/360003
55 https://www.statnews.com/2020/10/20/dry-technical-but-important-why-an-fda-advisory-panels-meeting-on-
covid-19-vaccines-matters/
56 https://openpaymentsdata.cms.gov/physician/1036685
57 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543330/pdf/ciaa1425.pdf
58 https://openpaymentsdata.cms.gov/physician/292920
59 https://openpaymentsdata.cms.gov/hospital/340030
60 https://www.statnews.com/2020/10/20/dry-technical-but-important-why-an-fda-advisory-panels-meeting-on-
covid-19-vaccines-matters/
61 https://openpaymentsdata.cms.gov/physician/292920
62 https://pubmed.ncbi.nlm.nih.gov/32726529/
63 https://openpaymentsdata.cms.gov/company/100000136554
Case 2:21-cv-00702-CLM   Document 1-12   Filed 05/19/21   Page 12 of 12

File and source

File

gov.uscourts.alnd.177186.1.12.pdf

Size

250,257 bytes

SHA-256

02029147f30c6c103c0c32e761c1a21175d0ec1f9cf13c9331f6b713a6199788

Our copy

gov.uscourts.alnd.177186.1.12.pdf

Original

archive.org